Cysteinyl leukotrienes (CysLTs) are associated with several inflammatory processes, including asthma. Due to this association, considerable effort has been invested in the development of antagonists to the CysLT receptors (CysLT(1)R). Many of these molecules have been shown to specifically interact with CysLT(1)R, but little is known about their impact on the conformation of the receptor and it...

The cysteinyl leukotrienes (C4, D4 and E4) are lipid mediators which are implicated in producing an array of effects such as bronchoconstriction, increased vascular permeability, mucous secretion, inflammatory cell recruitment and airway smooth muscle proliferation. Antagonism of the effects of cysteinyl leukotrienes can be achieved by drugs preventing their synthesis using a 5-lipoxygenase inh...

Pathophysiological conditions challenge cell volume homeostasis and perturb cell volume regulatory mechanisms leading to alterations of cell metabolism, active transepithelial transport, cell migration, and death. We report that inhibition of the 5-lipoxygenase (5-LO) with AA861 or ETH 615-139, the cysteinyl leukotriene 1 receptor (CysLT₁) with the antiasthmatic drug Zafirlukast, or the volume-...

BACKGROUND Cysteinyl leukotrienes (CysLT) are a class of inflammatory mediators synthesized by eosinophils and mast cells through the breakdown of arachidonic acid. They are known to play a key role in the molecular pathophysiology of asthma and chronic rhinosinusitis (CRS), promoting bronchoconstriction, mucus production, edema, and chemotaxis of neutrophils and eosinophils. Indeed, upregulati...